Infosys Limited vs Medtronic PLC — how do they compare? Infosys Limited trades at $11.18 (market cap $46.65B), while Medtronic PLC trades at $82.79 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 2.3× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| INFY | MDT | |
|---|---|---|
Market Cap | $46.65B | $106.61B |
Sector | Technology | Health |
52-Week High | $20.22 | $105.35 |
52-Week Low | $10.49 | $73.75 |
Enterprise Value | $43.87B | $125.36B |
Dividend Yield | 4.63% | 3.46% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medtronic (MDT) trades at $82.35, down 1.02% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.39. Revenue grew to $33.54B in 2025, with a net income margin of 13.2%. Recent news highlights the acquisition of SPR and the launch of AI-powered surgical technology, signaling innovation-driven growth.
The outlook for MDT is positive, supported by analyst consensus with a $97.50 price target and 58% buy ratings. Key opportunities include robust cash flow and dividend stability, while risks involve rising debt levels and competitive pressures in medtech. The stock presents a value proposition with a P/E of 22.33, trading below the consensus target.
Trailing returns across standard periods
Latest headlines on both assets
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →